Evommune, Inc. (EVMN) AI Stock Analysis

• Market Cap: $669.89M
• Dividend Yield: N/A
• Average Volume (3M): 272.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.72
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 31,524,094
• 10 Day Avg. Volume: 66,840
• 30 Day Avg. Volume: 272,690
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $38.60
• Price Target Upside: 96.94% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $21.00 ▲(7.14% Upside)

The score is primarily held down by weak financial performance: widening losses, accelerating cash burn, and a highly leveraged balance sheet with negative equity. Technicals provide some offset with positive near-term momentum (price above DMA20 and positive MACD), but valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.

Positive Factors

High Gross Margins

Sustained gross margins near 80–82% indicate durable product or cost structure advantages versus revenues. As sales scale, these margins can drive operating leverage, meaning incremental revenue could flow to the bottom line faster if fixed R&D and SG&A are better absorbed.

Revenue Growth Trend

Top-line growth from $5M to $7M shows early commercial or trial-driven traction rather than flat stagnation. While the base is small, consistent revenue growth combined with high gross margins creates a clearer path to scale and margin expansion if the company sustains or accelerates this trend.

Focused Therapeutic Niche

A clear strategic focus on immune-mediated inflammatory diseases concentrates R&D resources and builds domain expertise. This specialization can create durable competitive barriers, clearer go-to-market strategies, and steady demand given chronic nature of many immune conditions.

Negative Factors

Accelerating Cash Burn

Operating cash outflows nearly doubled year-over-year, sharply shortening runway absent new capital or spending cuts. Persistent heavy burn forces recurrent financing, increases dilution risk, and can constrain long-term R&D plans or commercialization investments critical for biotech success.

Negative Equity & Rising Debt

Worsening negative equity alongside rising debt signals a highly stressed balance sheet and limited financial flexibility. High leverage elevates refinancing risk, increases cost of capital, and can restrict strategic options, making the company vulnerable if funding markets tighten.

Losses Far Exceed Revenue

Net losses roughly doubled while revenues remain in the low single-digit millions, indicating profitability is distant. The mismatch between costs and revenue heightens execution and financing risk: reaching breakeven requires significant revenue scale or material cost restructuring.

Evommune, Inc. Business Overview & Revenue Model

Company Description

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

How the Company Makes Money

Evommune, Inc. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023
Income Statement
Total Revenue	7.00M	5.00M
Gross Profit	5.71M	4.00M
EBITDA	-65.49M	-32.99M
Net Income	-66.81M	-34.05M
Balance Sheet
Total Assets	76.06M	82.25M
Cash, Cash Equivalents and Short-Term Investments	72.04M	79.08M
Total Debt	193.31M	150.63M
Total Liabilities	220.29M	159.96M
Stockholders Equity	-144.24M	-77.71M
Cash Flow
Free Cash Flow	-58.28M	-30.09M
Operating Cash Flow	-58.20M	-29.97M
Investing Cash Flow	-3.99M	-48.43M
Financing Cash Flow	49.42M	63.75M

Evommune, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OCGN	54 Neutral	$587.16M	-7.48	-289.93%	―	14.26%	-23.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALT	51 Neutral	$436.15M	-3.97	-52.61%	―	-61.54%	31.25%
VIR	50 Neutral	$948.83M	-1.71	-49.06%	―	-78.55%	7.74%
EVMN	49 Neutral	$669.89M	―	―	―	―	―
VALN	48 Neutral	$885.22M	-7.32	-54.42%	―	14.86%	-1440.45%
ARCT	46 Neutral	$219.64M	-3.09	-27.43%	―	-41.53%	-11.32%